Efficacy and Safety of the Innovative Monoclonal Antibodies in Adults With Generalized Myasthenia Gravis: a Bayesian Network Analysis
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663412/
A series of clinical trials support the effectiveness of monoclonal antibodies for generalized myasthenia gravis (MG) compared to the placebo, but the priority among drugs remains unclear. Therefore, we conduct...
Eculizumab, rozanolixzumab 7 mg/kg, rozanolixzumab 10 mg/kg, and zilucoplan all demonstrated effectiveness versus placebo across all efficacy outcomes, including the MG-ADL, QMG, MGC, and MG-QoL 15r scores.
Burden of Illness and Costs in Patients With Myasthenia Gravis Currently Receiving Treatment in the United States
Source : https://pubmed.ncbi.nlm.nih.gov/38018505/
The burden of crises/exacerbations was substantially higher and healthcare costs were considerably greater in patients with MG treated with chronic IVIg or multiple NSISTs than in patients not receiving these...
Findings from this study indicate that median annual estimated MG-related total healthcare costs for patients who receive chronic treatment with IVIG or multiple NSISTs are several-fold higher than for patients with apparently well-controlled MG symptoms.
Factors Associated With the Disease Family Burden of Caregivers of Myasthenia Gravis Patients in Northwestern China: a Cross-Sectional Study
Source : https://pubmed.ncbi.nlm.nih.gov/37988975/
Depression symptom level, MG severity classification and family's monthly per capita income are independent factors related to the caregivers' disease family burden for MG patients.
The daily activity burden of the family and the economic burden of the family were the heaviest among the six dimensions of the caregivers' family disease burdens.
Single Institution Experience With Efgartigimod in Patients With Myasthenia Gravis: Patient Selection, Dosing Schedules, Treatment Response, and Adverse Events
Source : https://pubmed.ncbi.nlm.nih.gov/37990374/
This study found efgartigimod to be efficacious, well tolerated, and safe in patients with MG. Efgartigimod should be considered as an add-on therapy, a bridge therapy, or as a monotherapy...
Patients treated with efgartigimod significantly improved their MG-ADL score by an average of 5.5 and 7.1 points by 3 and 6 months, respectively.
A Case of Anti-Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis With Anti-Titin Antibody and Anti-Kv1.4 Antibody Positive Inflammatory Myopathy
Source : https://pubmed.ncbi.nlm.nih.gov/37989286/
An 84-year-old man was diagnosed with anti-acetylcholine receptor (AChR) antibody-positive ocular myasthenia gravis (OMG) at the age of 77 and received treatment. The patient was referred to our department with...
Evaluation of disease activity with serum anti-AChR antibody levels, and assessment of prognosis with examining antistriational antibodies are necessary for appropriate management of IM associated with MG.